Systemic Inflammation

Description

Inflammation is the body's biological response to harmful stimuli, designed to eliminate threats and initiate repair. It is driven by immune signaling molecules called cytokines, including IL-1ÎČ, IL-6, and TNF-α. These cytokines coordinate immune cells, increase blood flow, and trigger protective reactions. While short-term (acute) inflammation is essential for healing, chronic inflammation becomes harmful and contributes to metabolic dysfunction, autoimmune activation, and hormonal disruption.

Cytokine-driven inflammation: IL-1ÎČ and TNF-α activate immune cells and raise inflammatory signaling throughout the body, while IL-6 links the immune system to metabolic stress and often rises in response to blood sugar instability, visceral fat, and gut-derived endotoxins. When these cytokines stay elevated, they chronically stimulate the HPA axis, increase oxidative stress, and disrupt normal tissue function.

Carbohydrates, insulin resistance, and inflammation: High-glycemic and refined carbohydrates rapidly spike blood glucose and insulin. Over time this leads to insulin resistance, where cells respond poorly to insulin and require higher levels to clear glucose. Elevated insulin activates inflammatory pathways like NF-ÎșB and increases oxidative stress. Fluctuating glucose levels drive IL-6 and TNF-α release. As insulin resistance progresses, the body enters a state of persistent low-grade inflammation driven by metabolic stress and cytokine output from adipose tissue.

Leaky gut as a driver of systemic inflammation: A weakened intestinal barrier allows bacterial fragments (endotoxins such as LPS) to enter the bloodstream. These endotoxins strongly stimulate inflammatory cytokines and activate Toll-like receptors (TLR4), causing the immune system to treat gut-derived molecules as threats. This elevates IL-1ÎČ, IL-6, and TNF-α and can trigger autoimmune mechanisms. Carbohydrate-heavy and processed diets worsen gut permeability, while low-carbohydrate, ketogenic, and carnivore diets often improve barrier integrity and reduce endotoxin load.

Walking and inflammation reduction: Walking is one of the most effective natural interventions for reducing chronic inflammation. Rhythmic low-intensity movement lowers circulating IL-6, TNF-α, and CRP, increases anti-inflammatory cytokines such as IL-10, and improves glucose disposal without triggering stress hormones or sympathetic activation. Walking enhances lymphatic flow, improves blood circulation to tissues, and accelerates the clearance of inflammatory byproducts. It also strengthens vagal tone, which directly suppresses inflammatory signaling through the cholinergic anti-inflammatory pathway. Ancient humans routinely walked 6–10 km per day, meaning our inflammatory and metabolic systems evolved to expect this steady, rhythmic movement as a baseline regulator.

Metabolic inflammation: When chronic inflammation, insulin resistance, and leaky gut coexist, the immune system remains continuously activated. This disrupts the HPA axis, increases cortisol demand, creates fatigue, worsens metabolic health, contributes to mood disorders, and drives chronic disease. Reducing inflammatory signaling therefore requires stabilizing blood sugar, improving gut integrity, lowering dietary carbohydrates, reducing endotoxin exposure, and engaging in consistent low-intensity movement such as walking.

Mechanisms that promote this

[ 4 ] Steven E Shoelson et al. (2006) DOI PMID
[ 21 ] G Sigthorsson et al. (1998) DOI PMID [ 22 ] Patrice D Cani et al. (2008) DOI PMID [ 23 ] Alessio Fasano et al. (2012) DOI PMID [ 24 ] Thomas Y Ma et al. (2004) DOI PMID [ 25 ] Rana Al-Sadi et al. (2013) DOI PMID

Mechanisms affected by this

[ 26 ] Chieh-Hsin Lee et al. (2019) DOI PMID
[ 4 ] Steven E Shoelson et al. (2006) DOI PMID
[ 22 ] Patrice D Cani et al. (2008) DOI PMID [ 23 ] Alessio Fasano et al. (2012) DOI PMID [ 24 ] Thomas Y Ma et al. (2004) DOI PMID [ 25 ] Rana Al-Sadi et al. (2013) DOI PMID

Diseases affected by this mechanism

[ 1 ] Adriana Farcas et al. (2023) DOI PMID [ 2 ] A C Altamura et al. (1999) DOI PMID
[ 3 ] G S Hotamisligil et al. (1995) DOI PMID [ 4 ] Steven E Shoelson et al. (2006) DOI PMID [ 5 ] B Balkan et al. (1999) DOI PMID [ 6 ] A D Pradhan et al. (2001) DOI PMID [ 7 ] Marc Y Donath et al. (2011) DOI PMID [ 8 ] Claus M Larsen et al. (2007) DOI PMID [ 9 ] Allison B Goldfine et al. (2013) DOI PMID
[ 10 ] Xiushen Li et al. (2024) DOI PMID [ 11 ] Csanád Endre LƑrincz et al. (2025) DOI PMID [ 12 ] Jim Parker et al. (2025) DOI PMID [ 13 ] Antonio Mancini et al. (2021) DOI PMID

Symptoms connected to this mechanism

[ 14 ] Young Bok Lee et al. (2019) DOI PMCID PMID [ 15 ] Yongqiong Deng et al. (2018) DOI PMID [ 16 ] Brigitte Dréno et al. (2020) DOI PMCID PMID [ 17 ] Laetitia Penso et al. (2020) DOI PMCID PMID
[ 18 ] Jun Jie Lim et al. (2024) DOI PMCID PMID [ 19 ] Proietti Ilaria et al. (2023) DOI PMCID PMID [ 20 ] M Mansilla-Polo et al. (2024) DOI PMID
[ 18 ] Jun Jie Lim et al. (2024) DOI PMCID PMID [ 19 ] Proietti Ilaria et al. (2023) DOI PMCID PMID [ 20 ] M Mansilla-Polo et al. (2024) DOI PMID
[ 18 ] Jun Jie Lim et al. (2024) DOI PMCID PMID [ 19 ] Proietti Ilaria et al. (2023) DOI PMCID PMID [ 20 ] M Mansilla-Polo et al. (2024) DOI PMID

Sources

[1] Cortisol and cytokines in schizophrenia: A scoping review
[ 1 ] Adriana Farcas et al. (2023) DOI PMID
[2] HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment
[ 2 ] A C Altamura et al. (1999) DOI PMID
[3] Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.
[ 3 ] G S Hotamisligil et al. (1995) DOI PMID
[4] Inflammation and insulin resistance.
[ 4 ] Steven E Shoelson et al. (2006) DOI PMID
[5] Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats
[ 5 ] B Balkan et al. (1999) DOI PMID
[6] C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
[ 6 ] A D Pradhan et al. (2001) DOI PMID
[7] Type 2 diabetes as an inflammatory disease
[ 7 ] Marc Y Donath et al. (2011) DOI PMID
[8] Interleukin-1-receptor antagonist in type 2 diabetes mellitus
[ 8 ] Claus M Larsen et al. (2007) DOI PMID
[9] Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD)
[ 9 ] Allison B Goldfine et al. (2013) DOI PMID
[10] When IGF-1 Meets Metabolic Inflammation and Polycystic Ovary Syndrome
[ 10 ] Xiushen Li et al. (2024) DOI PMID
[11] Mechanisms and Target Parameters in Relation to Polycystic Ovary Syndrome and Physical Exercise: Focus on the Master Triad of Hormonal Changes, Oxidative Stress, and Inflammation
[ 11 ] Csanád Endre LƑrincz et al. (2025) DOI PMID
[12] Recognizing the Role of Insulin Resistance in Polycystic Ovary Syndrome: A Paradigm Shift from a Glucose-Centric Approach to an Insulin-Centric Model
[ 12 ] Jim Parker et al. (2025) DOI PMID
[13] Oxidative Stress and Low-Grade Inflammation in Polycystic Ovary Syndrome: Controversies and New Insights
[ 13 ] Antonio Mancini et al. (2021) DOI PMID
[14] Potential Role of the Microbiome in Acne: A Comprehensive Review
[ 14 ] Young Bok Lee et al. (2019) DOI PMCID PMID
[15] Patients with Acne Vulgaris Have a Distinct Gut Microbiota in Comparison with Healthy Controls
[ 15 ] Yongqiong Deng et al. (2018) DOI PMID
[16] The Skin Microbiome: A New Actor in Inflammatory Acne
[ 16 ] Brigitte Dréno et al. (2020) DOI PMCID PMID
[17] Association Between Adult Acne and Dietary Behaviors: Findings From the NutriNet-Santé Prospective Cohort Study
[ 17 ] Laetitia Penso et al. (2020) DOI PMCID PMID
[18] Dietary Patterns and their Impact on Atopic Dermatitis: A Comprehensive Review
[ 18 ] Jun Jie Lim et al. (2024) DOI PMCID PMID
[19] The Role of the Western Diet on Atopic Dermatitis: Our Experience and Review of the Current Literature
[ 19 ] Proietti Ilaria et al. (2023) DOI PMCID PMID
[20] Popular Diets and Skin Effects: A Narrative Review
[ 20 ] M Mansilla-Polo et al. (2024) DOI PMID
[21] Intestinal permeability and inflammation in patients on NSAIDs
[ 21 ] G Sigthorsson et al. (1998) DOI PMID
[22] Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice
[ 22 ] Patrice D Cani et al. (2008) DOI PMID
[23] Intestinal Permeability and its Regulation by Zonulin: Diagnostic and Therapeutic Implications
[ 23 ] Alessio Fasano et al. (2012) DOI PMID
[24] TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation
[ 24 ] Thomas Y Ma et al. (2004) DOI PMID
[25] TNF-α modulation of intestinal epithelial tight junction barrier is regulated by ERK1/2 activation of Elk-1
[ 25 ] Rana Al-Sadi et al. (2013) DOI PMID
[26] The Role of Inflammation in Depression and Fatigue
[ 26 ] Chieh-Hsin Lee et al. (2019) DOI PMID